A cocktail of antibodies for COVID-19 therapy


Treatment of infectious disease with single monoclonal antibodies (mAbs) can exert a selective pressure that potentially increases the possibility of mutational escape of the targeted antigen. This risk can be reduced through the combination of multiple mAbs targeting non-overlapping epitopes. In this preprint, Baum et al. show the protective effects of REGN-COV2, a cocktail of two fully humanized mAbs that bind to different regions of the SARS-CoV-2 spike protein. Rhesus macaques and golden hamsters treated with REGN-COV2 have markedly lower levels of detectable sub-genomic viral mRNA in both prophylactic and therapeutic settings. In rhesus macaques, the mRNA decrease is evident in oral and nasopharyngeal swabs, as well as in bronchoalveolar lavage. Combined-phase clinical trials for REGN-COV2 are underway.


Original article

  1. Baum, A. et al. REGN-COV2 antibody cocktail prevents and treats SARS-CoV-2 infection in rhesus macaques and hamsters. Preprint at bioRxiv (2020)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Dean B. Matthews.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Matthews, D.B. A cocktail of antibodies for COVID-19 therapy. Nat Rev Immunol 20, 591 (2020).

Download citation


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing